NCT02975687View on ClinicalTrials.gov

CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions
Acute Lymphoblastic Leukemia, Adult B-CellAcute Lymphoblastic Leukaemia Recurrent
Interventions
BIOLOGICAL

CD19 CAR T cells

CD19 CAR T cells was transduced with a lentiviral vector to express anti-CD19 scFv TCRζ:4-1BB.

Trial Locations (1)

300020

Institute of Hematology & Blood Diseases Hospital, Tianjin

Sponsors
All Listed Sponsors
collaborator

Juventas Cell Therapy Ltd.

INDUSTRY

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER